These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 34916166)
1. Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma. Miyake M; Shimizu T; Nishimura N; Kiba K; Maesaka F; Oda Y; Tachibana A; Tomizawa M; Ohmori C; Matsumura Y; Ichikawa K; Mizobuchi S; Yoshikawa T; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K; Clin Genitourin Cancer; 2022 Apr; 20(2):196.e1-196.e9. PubMed ID: 34916166 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine Plus Cisplatin Split Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A; Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy. Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Shelley M; Cleves A; Wilt TJ; Mason M Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413 [TBL] [Abstract][Full Text] [Related]
6. Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma. Sugimoto K; Taguchi S; Kishitani K; Kawai T; Masuda K; Nakamura Y; Kinjo M; Tambo M; Miyakawa J; Akiyama Y; Yamada Y; Sato Y; Yamada D; Nakagawa T; Fukuhara H; Kume H BMC Urol; 2022 Nov; 22(1):177. PubMed ID: 36352389 [TBL] [Abstract][Full Text] [Related]
7. Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study. Shindo T; Maehana T; Tanaka T; Hashimoto K; Kobayashi K; Takahashi A; Hotta H; Kunishima Y; Taguchi K; Tachiki H; Ito N; Matsukawa M; Kato R; Miyamoto S; Hinotsu S; Masumori N Int J Urol; 2022 Sep; 29(9):1010-1016. PubMed ID: 35654444 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180 [TBL] [Abstract][Full Text] [Related]
9. A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape. Gong J; Reimers MA Adv Ther; 2024 Sep; 41(9):3441-3451. PubMed ID: 39023740 [TBL] [Abstract][Full Text] [Related]
10. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866 [TBL] [Abstract][Full Text] [Related]
11. Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer. Yoneyama T; Imai A; Hatakeyama S; Hashimoto Y; Koie T; Ohyama C Int J Clin Oncol; 2015 Dec; 20(6):1179-84. PubMed ID: 26007690 [TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy. Huang J; Su R; Chen Z; Jiang S; Chen M; Yuan Y; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Li C; Wang Z; Bao Y; Cai M; Guo J; Wei Q; Xue W Oncoimmunology; 2022; 11(1):2124691. PubMed ID: 36148322 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A; Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911 [TBL] [Abstract][Full Text] [Related]
15. Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. Shelley MD; Cleves A; Wilt TJ; Mason MD BJU Int; 2011 Jul; 108(2):168-79. PubMed ID: 21718430 [TBL] [Abstract][Full Text] [Related]
16. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder]. Song Y; Yang L; Zhou A; Chi Y; Wang J Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283 [TBL] [Abstract][Full Text] [Related]
17. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287 [TBL] [Abstract][Full Text] [Related]
18. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352 [TBL] [Abstract][Full Text] [Related]
19. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100 [TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report. Hoshi S; Ohyama C; Ono K; Takeda A; Yamashita S; Yamato T; Itoh A; Satoh M; Saito S; Okada Y; Sohma F; Arai Y Int J Clin Oncol; 2004 Apr; 9(2):125-9. PubMed ID: 15108045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]